Stevanato Group S.p.A. Ordinary Shares (NY:STVN)

Stevanato Group (NYSE:STVN) reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its...

Stevanato Group Q2 Earnings Call Highlights ↗

August 09, 2026

Via MarketBeat

Performance

52-Week Range 27.8% below 52-week high

20.20

12.8952W Low 27.9952W High

1 Week 6.3% below 1-week high

19.511W Low 21.571W High

Stevanato Group S.p.A. Ordinary Shares (STVN) traded between $12.89 and $27.99 over the past 52 weeks and last traded at $20.20, 27.8% below its 52-week high. Over the past week it ranged between $19.51 and $21.57.

Past 12 Months

-4.4%

-2.5%

+6.3%

+47.1%

-1.8%

-23.0%

1W -$0.93

1M -$0.51

3M +$1.20

6M +$6.47

YTD -$0.38

1Y -$6.04

STVN was -23.0% over the past year, +47.1% over six months, -1.8% year to date, -4.4% in the last week.

12 Months vs Market

STVN

-23.0%

DIA

+10.1%

SPY

+15.1%

QQQ

+24.3%

IWM

+16.1%

Over the past 12 months STVN returned -23.0% versus DIA (Dow) +10.1%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +16.1%.

Volume & Liquidity 0.51× 3-mo avg

Today 189,921 3-mo avg 370.1K

238.9K

303.1K

370.1K

415.7K

YTD

509.1K

455.9K

STVN most recently traded 189,921 shares against a 3-month average daily volume of 370.1K.

More News

Stevanato (STVN) Q2 2026 Earnings Call Transcript ↗

August 04, 2026

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Stevanato Group Q2 2026 Earnings Call: Complete Transcript ↗

August 04, 2026

Via Benzinga

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

August 04, 2026

Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries

July 30, 2026

Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026

July 21, 2026

From Stevanato Group S.p.A

2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now ↗

June 09, 2026

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

June 08, 2026

From Stevanato Group

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting

June 03, 2026

Stevanato (STVN) Q1 2026 Earnings Transcript ↗

May 08, 2026

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

May 07, 2026

Stevanato Group to Participate in Three Upcoming Investor Conferences

May 04, 2026

Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026

April 23, 2026

From Stevanato Group

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

March 12, 2026

End of an Era: West Pharmaceutical Shares Slide as Longtime CEO Eric Green Announces Retirement

March 11, 2026

Via MarketMinute

Stevanato (STVN) Q4 2025 Earnings Call Transcript ↗

March 04, 2026

Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins

March 04, 2026

Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026

February 19, 2026

From Stevanato Group

The Biotech Revolution’s Ultimate ‘Picks and Shovels’ Play: A Deep Dive into West Pharmaceutical Services (WST)

December 23, 2025

Via MarketMinute

Picks and Shovels of the Biotech Revolution: A Deep Dive into West Pharmaceutical Services (WST)

December 23, 2025

Via PredictStreet

Stevanato (STVN) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

Stevanato Group SPA (NYSE:STVN) Tops Q3 2025 Earnings and Revenue Estimates ↗

November 06, 2025

Via Chartmill

Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

November 06, 2025